Treatment of Conditions that Increase in Severity and/or Occurrence During One or More Phases of the Menstrual Cycle

Abstract

Methods are provided for treating a subject for a condition. In accordance with the subject methods, at least a portion of a subject's autonomic nervous system is modulated during at least one predetermined phase of the subject's menstrual cycle to alter the parasympathetic activity/sympathetic activity ratio in a manner that is effective to treat the subject for the condition. The subject methods find use in the treatment of a variety of different conditions, including various disease conditions, that increase in severity and/or occurrence during one or more phases of the menstrual cycle. Also provided are systems and kits for use in practicing the subject methods.

1 .- 68 . (canceled) 
     
     
         69 . A multi-dose package comprising:
 a first unit dosage of an active agent and   a second unit dosage of the active agent;   wherein the amount of the active agent in the first unit dosage differs from the amount of the active agent in the second unit dosage, and   wherein the unit dosages of the active agent are selected to treat a subject for a condition that is increased in severity or occurrence during one or more phases of the menstrual cycle.   
     
     
         70 . The multi-dose package according to  claim 69 , wherein the multi-dose package is in the form of a monthly package. 
     
     
         71 . The multi-dose package according to  claim 69 , wherein the multi-dose package is in the form of a seasonal package. 
     
     
         72 . The multi-dose package according to  claim 69 , wherein the multi-dose package is in the form of a yearly package. 
     
     
         73 . The multi-dose package according to  claim 69 , wherein the package further comprises a placebo. 
     
     
         74 . The multi-dose package according to  claim 69 , wherein the unit dosages are configured for oral administration. 
     
     
         75 . The multi-dose package according to  claim 69 , wherein the package further comprises a second active agent. 
     
     
         76 . The multi-dose package according to  claim 69 , wherein the unit dosages of the second active agent are selected to treat a subject for a second condition that is increased in severity or occurrence during one or more phases of the menstrual cycle. 
     
     
         77 . The multi-dose package according to  claim 69 , wherein the package is tailored for a particular subject. 
     
     
         78 . The multi-dose package according to  claim 69 , wherein the condition is chosen from cardiovascular conditions; neurodegenerative conditions; neuroinflammatory conditions; orthopedic inflammatory conditions; lymphoproliferative conditions; autoimmune; inflammatory conditions; infectious diseases; pulmonary conditions; transplant-related conditions; gastrointestinal conditions; endocrine conditions; genitourinary conditions; skin conditions; aging-associated conditions; neurologic conditions; Th-2 dominant conditions; conditions that cause hypoxia; conditions that cause hypercarbia; conditions that cause hypercapnia; conditions that cause acidosis; conditions that cause acidemia; OB-GYN conditions; sudden death syndromes; peripartum and pregnancy related disorders; fibrosis; post-operative recovery conditions; post-procedural recovery conditions; chronic pain; trauma; bacterial infections; and fibromyalgia. 
     
     
         79 . The multi-dose package according to  claim 69 , wherein the active agent is chosen from: statins; beta-blockers; diuretics; calcium channel blockers; angiotensin converting enzyme (ACE) inhibitors; beta agonists; antihistamines; steroids; anticoagulants; and diabetes agents. 
     
     
         80 . The multi-dose package according to  claim 69 , wherein the active agent is a statin. 
     
     
         81 . The multi-dose package according to  claim 69 , wherein the active agent is a beta-blocker. 
     
     
         82 . The multi-dose package according to  claim 69 , wherein the active agent is a diuretic. 
     
     
         83 . The multi-dose package according to  claim 69 , wherein the active agent is a calcium channel blocker. 
     
     
         84 . The multi-dose package according to  claim 69 , wherein the active agent is an angiotensin converting enzyme (ACE) inhibitor. 
     
     
         85 . The multi-dose package according to  claim 69 , wherein the active agent is a beta agonist. 
     
     
         86 . The multi-dose package according to  claim 69 , wherein the active agent is an anti-histamine. 
     
     
         87 . The multi-dose package according to  claim 69 , wherein the active agent is a steroid. 
     
     
         88 . The multi-dose package according to  claim 69 , wherein the active agent is an anticoagulant. 
     
     
         89 . The multi-dose package according to  claim 69 , wherein the active agent is a diabetes agent. 
     
     
         90 . A method of treating a subject for a condition that is increased in severity or occurrence during one or more phases of the menstrual cycle, the method comprising:
 administering to a subject one of a plurality of unit dosage forms of an active agent contained in a single multi-dose package comprising:   a first unit dosage of an active agent and   a second unit dosage of the active agent;   wherein the amount of the active agent in the first unit dosage differs from the amount of the active agent in the second unit dosage, and   wherein the unit dosages of the active agent are selected to treat a subject for a condition that is increased in severity or occurrence during one or more phases of the menstrual cycle.